Q/C TECHNOLOGIES, INC.

QCLS

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0001321834

SEC filings (opens in a new tab)

Insider trades, last 90 days

None

No open-market purchases or sales were filed in the last 90 days.

View insider trades

13F holders, Q2 2026

21

+3 vs. Q1 2026
Total value $2.87M

View 13F holders

Superinvestors holding QCLS

0

None of the superinvestors held QCLS at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by QCLS insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
May 14, 2026	Mar 30, 2026	Voss Chelsea SierraDirector	PPurchaseCommon stock	+1.75K	$3.15	+$5.52K	61.56K	+2.9%	SEC
Nov 18, 2025	Sep 4 – Nov 14, 2025	PharmaCyte Biotech, Inc.10% Owner	PPurchaseCommon stock, par value $0.001 per share · Derivative	+1.78M	–	–	889.87K	–	SEC
Aug 24, 2023	Aug 24, 2023	Rivard PaulChief Legal Officer	PPurchaseCommon stock	+150K	$1.11	+$166.5K	400K	+60.0%	SEC
Aug 18, 2023	Aug 17, 2023	Rivard PaulChief Legal Officer	PPurchaseCommon stock	+25K	$1.12	+$28K	250K	+11.1%	SEC
Dec 8, 2022	Dec 8, 2022	Rivard PaulEVP of Operations, GC	PPurchaseCommon stock	+10K	$1.53	+$15.3K	225K	+4.7%	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in QCLS at the end of Q2 2026.

Institutions holding QCLS in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Quinn Opportunity Partners LLC	123,024	$479.79K	0.02%	−88,366−41.8%	Reduced
VANGUARD CAPITAL MANAGEMENT LLC	115,031	$448.62K	0.00%	+77,520+206.7%	Added
JANE STREET GROUP, LLC	87,241	$340.24K	0.00%	−38,947−30.9%	Reduced
GEODE CAPITAL MANAGEMENT, LLC	70,682	$275.66K	0.00%	+23,292+49.1%	Added
UBS Group AG	58,894	$229.69K	0.00%	−19,095−24.5%	Reduced